Antisense, RNA

• Chemical name: 1,1‘-((2-(4-(2-((2-(bis(2-hydroxydodecyl)amino)ethyl)(2-hydroxydodecyl)amino)ethyl)piperazin-1-yl)ethyl)azanediyl)bis(dodecan-2-ol) Application: Lipid NanoParticles as delivery systems for enabling the therapeutic potential of siRNA, mRNA or CRISPR as they exhibit remarkable in ...

Analytical development services for oligonucleotides: For oligo-based drugs, our capabilities range from GLP bioanalysis to GLP/cGMP characterisation. We support product development, from quality control testing of amidite starting materials and early stage product characterization through to GMP batch r...

Sumitomo Chemical has unique manufacturing technology for long (more than 100-mer) oligonucleotides with purity of 90%

We provide a wide range of discovery and development services for New Biological Entities (NBEs) from our state-of-the-art facility located in Hyderabad, India. At the core of NBE services is a talented team of scientists experienced in the design and delivery of a range of advanced therapeutic modalities ...

WuXi STA has an integrated Oligo API process R&D and manufacturing platform from preclinical to commercial, operating at our US FDA inspected integrated process R&D and manufacturing facility based in Changzhou, China. We support the development and manufacture of a variety of oligonucleotide modal...

Chemists at CordenPharma and the Otto-von-Guericke-University of Magdeburg, Germany developed a scalable synthesis of pharma-grade cholesterol based on botanical sources. This offers a large-scale production of highly needed cholesterol, which is used as part of the lipid cocktail ...

Characterization and analysis of mRNA supporting vaccine and therapeutic development, including assessing clinical translation efficiency and immunogenicity. At our GLP / GCP / GMP laboratories, scientists can test a mRNA drug substance or drug product to help you confidently assess batch to batch manufa...

• Unlabeled oligos • Custom DNA oligos • Custom RNA oligos • qPCR primer and Probe • siRNA, sgRNA, crRNA, ASO etc.

[TGF-β2 Targeting ASO (TASO) + IL-2 Combination therapy] - Phase Ib

1. Confirm the potential of TGF-β2 as a biomarker in human blood and tumor tissues from the efficacy result of Phase Ib clinical trial on cancer patients 

2. Confirm the suppression of IL-2’s side effect in combinati...